1. Immunogenicity and protection efficacy of a COVID-19 DNA vaccine encoding spike protein with D614G mutation and optimization of large-scale DNA vaccine production
- Author
-
Aytül Gül, Sedef Erkunt Alak, Hüseyin Can, Muhammet Karakavuk, Gülay Korukluoğlu, Ayşe Başak Altaş, Ceren Gül, Tuğba Karakavuk, Ahmet Efe Köseoğlu, Hivda Ülbeği Polat, Hilal Yazıcı Malkoçoğlu, Arzu Taş Ekiz, İrem Abacı, Özge Aksoy, Hakan Enül, Cumhur Adıay, Serdar Uzar, Fahriye Saraç, Cemal Ün, Adnan Yüksel Gürüz, Ayşe Gülten Kantarcı, Hasan Akbaba, Gülşah Erel Akbaba, Habibe Yılmaz, Aysu Değirmenci Döşkaya, Meltem Taşbakan, Hüsnü Pullukçu, Ercüment Karasulu, Şaban Tekin, and Mert Döşkaya
- Subjects
SARS-CoV-2 ,DNA vaccine ,K18-hACE2 transgenic mice ,Large-scale production ,Upstream ,Downstream ,Medicine ,Science - Abstract
Abstract Severe acute respiratory syndrome coronavirus 2 had devastating consequences for human health. Despite the introduction of several vaccines, COVID-19 continues to pose a serious health risk due to emerging variants of concern. DNA vaccines gained importance during the pandemic due to their advantages such as induction of both arms of immune response, rapid development, stability, and safety profiles. Here, we report the immunogenicity and protective efficacy of a DNA vaccine encoding spike protein with D614G mutation (named pcoSpikeD614G) and define a large-scale production process. According to the in vitro studies, pcoSpikeD614G expressed abundant spike protein in HEK293T cells. After the administration of pcoSpikeD614G to BALB/c mice through intramuscular (IM) route and intradermal route using an electroporation device (ID + EP), it induced high level of anti-S1 IgG and neutralizing antibodies (P
- Published
- 2024
- Full Text
- View/download PDF